FINWIRES · TerminalLIVE
FINWIRES

Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22

By

Sutro Biopharma (STRO) has an average rating of buy and mean price target of $35.73, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

RBC Upgrades Texas Roadhouse to Outperform From Sector Perform, Raises Price Target to $210 From $180

Texas Roadhouse (TXRH) has an average rating of overweight and mean price target of $195.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TXRH
Research

Morgan Stanley Downgrades Aardvark Therapeutics to Underweight From Equalweight, Cuts Price Target to $3 From $7

Aardvark Therapeutics (AARD) has an average rating of overweight and mean price target of $18.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AARD
Research

Morgan Stanley Downgrades Viking Holdings to Equalweight From Overweight, Raises Price Target to $86 From $81

Viking Holdings (VIK) has an average rating of overweight and mean price target of $92, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$VIK